Focus on skin cancer association and progression under TNF antagonist therapy

Expert Opinion on Biological Therapy

Volumn 11, Issue 9, 2011, Pages 1215-1222

  Piérard Franchimont, Claudine ^a   Piérard, Gérald E ^a   Quatresooz, Pascale ^a  

^a UNIVERSITY OF LIÈGE   (Belgium)

Author keywords

Basal cell carcinoma; Cancer progression; Malignant melanoma; Squamous cell carcinoma; TNF antagonist

Indexed keywords

ADALIMUMAB; CERTOLIZUMAB PEGOL; ETANERCEPT; GOLIMUMAB; INFLIXIMAB; METHOTREXATE; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR INHIBITOR;

APOPTOSIS; BREAST CANCER; CANCER GROWTH; CANCER RISK; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; HODGKIN DISEASE; HUMAN; IMMUNOCOMPROMISED PATIENT; INFECTION; LOW DRUG DOSE; LYMPHOMA; MELANOCYTIC NEVUS; MELANOMA; REVIEW; SKIN CANCER; TONSIL CANCER;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; HUMANS; IMMUNOTHERAPY; SKIN NEOPLASMS; TUMOR NECROSIS FACTOR-ALPHA;

ANIMALIA;

EID: 80051507104     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712598.2011.582463     Document Type: Review

References (94)

1. Uhoda I, Quatresooz P, Fumal I, et al. Updating trends in cutaneous cancers in south-east Belgium. Oncol Rep 2004;12:111-14
2. Walther U, Kron M, Sander S, et al. Risk and protective factors for sporadic basal cell carcinoma: results of a two-centre case-control study in southern Germany. Clinical actinic elastosis may be a protective factor. Br J Dermatol 2004;151:170-8 (Pubitemid 39061295)
3. Lichte V, Dennenmoser B, Dietz K, et al. Professional risk for skin cancer development in male mountain guides-a cross-sectional study. J Eur Acad Dermatol Venereol 2010;24:797-804
4. Lovatt TL, Lear JT, Bastrilles J, et al. Associations between ultraviolet radiation, basal cell carcinoma site and histology, host characteristics, and rate of development of further tumors. J Am Acad Dermatol 2005;52:468-73
5. Thirion L, Pierard-Franchimont C, Quatresooz P, et al. Basal cell carcinoma in a patient with psoriasis. Rev Med Liege 2006;61:795-6 (Pubitemid 351448377)
6. Pierard-Franchimont C, Quatresooz P, Paquet P, et al. A range of targeted treatments using monoclonal antibodies in dermatology. Current and future practice. Rev Med Liege 2009;64:334-8
7. Pierard GE, Goffin V, Hermanns-Le T, et al. Surfactant induced dermatitis. A comparison of corneosurfametry with predictive testing on human and reconstructed skin. J Am Acad Dermatol 1995;33:462-9
8. Wajant H, Scheurich P. TNFR1-induced activation of the classical NF-kappaB pathway. FEBS J 2011;278:862-76
9. Naude PJ, den Boer JA, Luiten PG, Eisel UL. Tumor necrosis factor receptor crosstalk. FEBS J 2011;278:888-98
10. Paquet P, Pierard GE. Toxic epidermal necrolysis: revisiting the tentative link between early apoptosis and late necrosis. Int J Mol Med 2007;19:3-10
11. Yoo J, Kim HR, Lee YJ. Hyperthermia enhances tumour necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis in human cancer cells. Int J Hyperthermia 2006;22:713-28 (Pubitemid 46332056)
12. Bogiatzi SI, Fernandez I, Bichet JC, et al. Cutting edge: proinflammatory and Th2 cytokines synergize to induce thymic stromal lymphopoietin production by human skin keratinocytes. J Immunol 2007;178:3373-7 (Pubitemid 46417601)
13. Paquet P, Nusgens B, Pierard GE. Lapiere ChM. Gelatinases in drug-induced toxic epidermal necrolysis. Eur J Clin Invest 1998;28:528-32 (Pubitemid 28350016)
14. Chakravarty EF, Michaud K, Wolfe F. Skin cancer, rheumatoid arthritis, and tumor necrosis factor inhibitors. J Rheumatol 2005;32:2130-5 (Pubitemid 41587856)
15. Pierard-Franchimont C, Pierard GE. Cutaneous adverse reactions to monoclonal antibody treatments. Rev Med Liege 2009;64:339-46
16. Langley RG, Gordon KB. Duration of remission of biologic agents for chronic plaque psoriasis. J Drugs Dermatol 2007;6:1205-12
17. Pierard GE, Pierard-Franchimont C, Szepetiuk G, et al. The therapeutic potential of TNFalpha antagonists for skin psoriasis comorbidities. Exp Opin Biol Ther 2010;10:1197-208
18. Maini RN, Breedveld FC, Kalden JR, et al. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum 1998;41:1552-63 (Pubitemid 28459913)
19. Klotz U, Teml A, Schwab M. Clinical pharmacokinetics and use of infliximab. Clin Pharmacokinet 2007;46:645-60 (Pubitemid 47204851)
20. Menter A, Tyring SK, Gordon K, et al. Adalimumab therapy for moderate to severe psoriasis: a randomized, controlled phase III trial. J Am Acad Dermatol 2008;58:106-15 (Pubitemid 350298146)
21. Boyce EG, Halilovic J, Stan-Ugbene O. Golimumab: review of the efficacy and tolerability of a recently approved tumor necrosis factor-alpha inhibitor. Clin Ther 2010;32:1681-703
22. Feagan BG, Sandborn WJ, Wolf DC, et al. Randomised clinical trial: improvement in health outcomes with certolizumab pegol in patients with active Crohn's diseases with prior loss of response to infliximab. Aliment Pharmacol Ther 2011;33:541-50
23. Keystone EC, Curtis JR, Fleischmann RM, et al. Rapid improvement in the signs and symptoms of rheumatoid arthritis following certolizumab pegol treatment predicts better longterm outcomes: post-hoc analysis of a randomized controlled trial. J Rheumatol 2011;published online 1 Mar 2011, doi:10.3899/jrheum.100935
24. Patel RV, Clark LN, Lebwohl M, et al. Treatments for psoriasis and the risk of malignancy. J Am Acad Dermatol 2009;60:1001-17
25. Dommasch ED, Abuabara K, Shin DB, et al. The risk of infection and malignancy with tumor necrosis factor antagonists in adults with psoriatic disease: a systematic review and meta-analysis of randomized controlled trials. J Am Acad Dermatol 2011;published online 18 February 2011, doi:10.1016/j.jaad. 2010.09.734
26. Sterry W, Barker J, Boehncke WH, et al. Biological therapies in the systemic management of psoriasis: international consensus conference. Br J Dermatol 2004;151:(Suppl 69):3-17 (Pubitemid 39215184)
27. Bongartz T, Sutton AJ, Sweeting MJ, et al. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA 2006;295:2275-85 (Pubitemid 43736578)
28. Smith CH, Jackson K, Bashir SJ, et al. Infliximab for severe treatment-resistant psoriasis: a prospective, open-label study. Br J Dermatol 2006;155:160-9 (Pubitemid 43876410)
29. Sheppard J, Raza K, Buckley CD. Skin cancer in psoriatic arthritis treated with anti-TNF therapy. Rheumatology 2007;46:1622-3 (Pubitemid 47500587)
30. Wolfe F, Michaud K. Biologic treatment of rheumatoid arthritis and the risk of malignancy: analyses from a large US observational study. Arthritis Rheum 2007;56:2886-95 (Pubitemid 47502734)
31. Chakravarty EF, Farmer ER. Risk of skin cancer in the drug treatment of rheumatoid arthritis. Expert Opin Drug Saf 2008;7:539-46
32. Menter A, Gottlieb A, Feldman SR, et al. Guideliens of care for the management of psoriasis and psoriatic arthritis: section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics. J Am Acad Dermatol 2008;58:826-50 (Pubitemid 351509656)
33. Maire C, Delesalle F, Carpentier O, et al. Multiple basal cell carcinomas after etanercept treatment for psoriasis. Ann Dermatol Venereol 2009;136:355-9
34. Askling J, Fahrbach K, Nordstrom B, et al. Cancer risk with tumor necrosis factor alpha (TNF) inhibitors: meta-analysis of randomized controlled trials of adalimumab etanercept, and infliximab using patient level data. Pharmacoepidemiol Drug Saf 2011;20:119-30
35. Di Lernia V, Ricci C. Cutaneous malignancies during treatment with efalizumab and infliximab: when temporal relationship does not mean causality. J Dermatol Treat 2010;published online 28 July 2010, doi:10.3109/ 09546631003681086
36. Fogo AJ, Hung JB, Clement M. Multiple cutaneous malignancies arising in a patient with Crohn disease treated with concomitant azathioprine and antitumour necrosis factor-alpha. Clin Exp Dermatol 2010;35:793-5
37. Katoulis AC, Kanelleas A, Zambacos G, et al. Development of two primary malignant melanomas after treatment with adalimumab: a case report and review of the possible link between biological therapy with TNF-alpha antagonists and melanocytic proliferation. Dermatology 2010;221:9-12
38. Naldi L. Malignancy concerns with psoriasis treatments using phototherapy, methotrexate, cyclosporine, and biologics: fact and controversies. Clin Dermatol 2010;28:88-92
39. Rahman N, Healy C, Flint SR, et al. Cautionary note: a possible association between oral squamous cell carcinoma and tumor necrosis factor antagonists: need for oral screening. J Clin Rheumatol 2010;16:197-9
40. Faurschou A. Role of tumor necrosis factor-alpha in the regulation of keratinocyte cell cycle and DNA repair after ultraviolet-B radiation. Dan Med Bull 2010;57:B4179
41. Deroose JP, Eggermont AM, van Geel AN, et al. Isolated limb perfusion for melanoma in-transit metastases: developments in recent years and the role of tumor necrosis factor alpha. Curr Opin Oncol 2011;23:183-8
42. Lacana E, Amur S, Mummannemi P, et al. The emerging role of pharmacogenomics in biologics. Clin Pharmacol Ther 2007;82:466-71 (Pubitemid 47414357)
43. Melnikova VO, Ananthaswamy HN. Cellular and molecular events leading to the development of skin cancer. Mutat Res 2005;571:91-106 (Pubitemid 40313435)
44. Harper N, Farrow SN, Kaptein A, et al. Modulation of tumor necrosis factor apoptosis-inducing ligand-induced NF-kappaB activation by inhibition of apical caspases. J Biol Chem 2001;276:34743-52
45. Diessenbacher P, Hupe M, Sprick MR, et al. NF-kappaB inhibition reveals differential mechanisms of TNF versus TRAIL-induced apoptosis upstream or at the level of caspase-8 activation independent of cIAP2. J Invest Dermatol 2008;128:1134-47 (Pubitemid 351543191)
46. Yang G, Xiao X, Rosen D, et al. The biphasic role of NF-kappaB in tumor progression and chemoresistance of ovarian cancer. Clin Cancer Res 2011;17:2181-94
47. Scott KA, Moore RJ, Arnott CH, et al. An anti-tumor necrosis factor-alpha antibody inhibits the development of experimental skin tumors. Mol Cancer Ther 2003;2:445-51
48. Arnott CH, Scott KA, Moore RJ, et al. Expression of both TNF-alpha receptor subtypes is essential for optimal skin tumour development. Oncogene 2004;23:1902-10 (Pubitemid 38445416)
49. Scott KA, Arnott CH, Robinson SC, et al. TNF-alpha regulates epithelial expression of MMP-9 and integrin alphavbeta6 during tumour promotion. A role for TNF-alpha in keratinocyte migration? Oncogene 2004;23:6954-66 (Pubitemid 39279996)
50. Lebwohl M. Actinic keratoses epidemiology and progression to squamous cell carcinoma. Br J Dermatol 2003;149:31-3 (Pubitemid 38064513)
51. Quatresooz P, Petit L, Uhoda I, et al. Mosaic subclinical melanoderma. An Achilles heel for UV-related epidermal carcinogenesis? Int J Oncol 2004;25:1763-8
52. Kwon OS, Yoo HG, Han JH, et al. Photoaging-associated changes in epidermal proliferative cell fractions in vivo. Arch Dermatol Res 2008;300:47-52 (Pubitemid 350231465)
53. Quatresooz P, Pierard-Franchimont C, Paquet P, et al. Angiogenic fast-growing melanomas and their micrometastases. Eur J Dermatol 2010;20:302-7
54. Quatresooz P, Pierard GE, Pierard-Franchimont C, et al. Molecular pathways supporting the proliferation staging of malignant melanoma. Int J Mol Med 2009;24:295-301
55. Quatresooz P, Xhaulfaire-Uhoda E, Pierard-Franchimont C, et al. Epidermal field carcinogenesis in bald-headed. An attempt at finetuning early non-invasive detection. Oncol Rep 2009;21:1313-16
56. Carlson JA, Scott D, Wharton J, et al. Incidental histopathologic pattern possible evidence of "field cancerisation" surrounding skin tumors. Am J Dermatopathol 2001;23:494-7
57. Brakhuis BJ, Tabor MP, Kummer JA, et al. A genetic explanation of Slaughter's concept of field cancerization evidence and clinical implications. Cancer Res 2003;63:1727-30 (Pubitemid 36460827)
58. Uhoda I, Quatresooz P, Pierard-Franchimont C, et al. Nudging epidermal field cancerogenesis by imiquimod. Dermatology 2003;206:357-60 (Pubitemid 36677030)
59. Fuchs A, Marmur E. The kinetics of skin cancer: progression of actinic keratosis to squamous cell carcinoma. Dermatol Surg 2007;33:1099-101 (Pubitemid 47339694)
60. Quatresooz P, Pierard-Franchimont C, Paquet P, et al. Crossroads between actinic keratosis and squamous cell carcinoma, and novel pharmacological issues. Eur J Dermatol 2008;18:6-10 (Pubitemid 351158165)
61. Long CC, Turner RJ, Marks R. Actinic keratoses: the bald facts. Arch Dermatol 1996;132:1132-3 (Pubitemid 26296579)
62. Zidi I, Mestiri S, Bartegi A, Amor NB. TNF-alpha and its inhibitors in cancer. Med Oncol 2010;27:185-98
63. Kyle S, Chandler D, Griffiths CE, et al. Guideline for anti-TNF-alpha therapy in psoriatic arthritis. Rheumatology 2005;44:390-7 (Pubitemid 40361300)
64. Franchimont C, Pierard GE, Van Cauwenberge D, et al. Episodic progression and regression of basal cell carcinomas. Br J Dermatol 1982;106:305-10 (Pubitemid 12176999)
65. Skov L, Allen MH, Bang B, et al. Basal cell carcinoma is associated with high TNF-alpha release but not with TNF-alpha polymorphism at position-308. Exp Dermatol 2003;12:772-6 (Pubitemid 38028668)
66. Tyring S, Gordon KB, Poulin Y, et al. Long term safety and efficacy of 50 mg of etanercept twice weekly in patients with psoriasis. Arch Dermatol 2007;143:719-26 (Pubitemid 46955730)
67. Bongarzt T, Sutton AJ, Sweeting MJ, et al. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA 2006;295:2275-85 (Pubitemid 43736578)
68. Brown SL, Greene MH, Gershon SK, et al. Tumor necrosis factor antagonist therapy and lymphoma development. Arthritis Rheum 2002;46:3151-8
69. Askling J, Fored SM, Baecklund E, et al. Haematopoietic malignancies in rheumatoid arthritis: lymphoma risk and characteristics after exposure to tumor necrosis factor antagonists. Ann Rheum Dis 2005;64:1414-20 (Pubitemid 41623850)
70. Chakravarty EF, Michaud K, Wolfe F. Skin cancer, rheumatoid arthritis, and tumor necrosis factor inhibitors. J Rheumatol 2005;32:2130-5 (Pubitemid 41587856)
71. Fryrear RS, Wiggins AK, Sangueza O, et al. Rapid onset of cutaneous squamous cell carcinoma of the penis in a patient with psoriasis on etanercept therapy. J Am Acad Dermatol 2004;51:1026 (Pubitemid 39593030)
72. Saabye Bogelund F, Ashlede Philipsen P, Gniadecki R. Factors affecting the recurrence rate of basal cell carcinoma. Acta Derm Venereol 2007;87:330-4
73. Euvrard S, Kanitakis J, Claudy A. Skin cancers after organ transplantation. N Engl J Med 2003;348:1681-91 (Pubitemid 36459475)
74. Paquet P, Arrese JE, Greimers R, et al. Eruptive speckled melanocytic nevi following drug-induced toxic epidermal necrolysis. Eur J Dermatol 1995;5:379-82
75. Shoji T, Cockerell CJ, Koff AB, et al. Eruptive melanocytic nevi after Stevens-Johnson syndrome. J Am Acad Dermatol 1997;37:337-9 (Pubitemid 27350007)
76. Bauer JW, Schaeppi H, Kaserer C, et al. Large melanocytic nevi in hereditary epidermolysis bullosa. J Am Acad Dermatol 2001;44:577-84 (Pubitemid 32249511)
77. Alaibac M, Piaserico S, Rossi CR, et al. Eruptive melanocytic naevi in patients with renal allografts: report of 10 cases with dermoscopic findings. J Am Acad Dermatol 2003;49:1020-2 (Pubitemid 37475472)
78. Katsanos KH, Christodoulou DK, Zioga A, et al. Cutaneous nevi pigmentosus during infliximab therapy in a patient with Crohn's disease: fallacy or coincidence? Inflamm Bowel Dis 2003;9:279
79. Woodhouse J, Maytin EV. Eruptive nevi of the palms and soles. J Am Acad Dermatol 2005;52:S96-100
80. Bovenschen HJ, Tjioe M, Vermaat H, et al. Induction of eruptive benign melanocytic naevi by immune suppressive agents, including biologicals. Br J Dermatol 2006;154:880-4
81. Richert S, Bloom EJ, Flynn K, et al. Widespread eruptive dermal and atypical melanocytic nevi in association with chronic myelocytic leukaemia: case report and review of the literature. J Am Acad Dermatol 1996;35:326-9 (Pubitemid 26257270)
82. Fulchiero GJ, Salvaggio H, Drabick JJ, et al. Eruptive latent metastatic melanomas after initiation of antitumor necrosis factor therapies. J Am Acad Dermatol 2007;56:S65-7 (Pubitemid 46552081)
83. Bourguignon JP, Pierard GE, Ernould C, et al. Effects of human growth hormone therapy on melanocytic naevi. Lancet 1993;341:1505-6 (Pubitemid 23168645)
84. Pierard GE, Pierard-Franchimont C, Nikkels AF, et al. Naevocyte triggering by recombinant human growth hormone. J Pathol 1996;180:74-9 (Pubitemid 26348895)
85. Kowalzick L, Eickenscheidt L, Komar M, et al. Long term treatment of psoriasis with TNF-alpha antagonists: occurrence of malignant melanoma. Hautarzt 2009;608:655-7
86. Gordon KB, Langley RG, Leonardi C, et al. Clinical response to adalimumab treatment in patients with moderate to severe psoriasis: double-blind, randomized controlled trial and open-label extension study. J Am Acad Dermatol 2006;55:598-606 (Pubitemid 44436647)
87. Khan I, Rahman L, McKenna DB. Primary cutaneous melanoma: a complication of infliximab treatment? Clin Exp Dermatol 2009;34:524-6
88. Bartelds GM, Wolbink GJ, Stapel S, et al. High levels of human anti-human antibodies to adalimumab in a patient not responding to adalimumab treatment. Ann Rheum Dis 2006;65:1249-50 (Pubitemid 44277411)
89. Wolbink GJ, Vis M, Lems W, et al. Development of antiinfliximab antibodies and relationship to clinical response in patients with rheumatoid arthritis. Arthritis Rheum 2006;54:711-15
90. Bartelds GM, Wijbrandts CA, Nurmohamed MT, et al. Clinical response to adalimumab: relationship to anti-adalimumab antibodies and serum adalimumab concentrations in rheumatoid arthritis. Ann Rheum Dis 2007;66:921-6 (Pubitemid 46999794)
91. West RL, Zelinkova Z, Wolbink GJ, et al. Immunogenicity negatively influences the outcome of adalimumab treatment in Crohn's disease. Aliment Pharmacol Ther 2008;28:1122-6
92. Lecluse LLA, Driessen RJB, Spuls PI, et al. Extent and clinical consequences of antibody formation against adalimumab in patients with plaque psoriasis. Arch Dermatol 2010;146:127-32
93. Wolbink GJ, Aarden LA, Dijkmans BA. Dealing with immunogenicity of biologicals: assessment and clinical relevance. Curr Opin Rheumatol 2009;21:211-15
94. Lecluse LL, Naldi L, Stern RS, et al. National registries of systemic treatment for psoriasis and the European "Psonet" initiative. Dermatology 2009;218:347-56